Literature DB >> 22591713

Is a QALY still a QALY at the end of life?

Jeff Round1.   

Abstract

Recent research into end of life and palliative care has focused on the development of a replacement for the quality adjusted life year (QALY) as an outcome measure. Reasons given range from the lack of anticipated survival benefit from treatment to the inappropriateness of death as an anchor for valuing health states, or the increased value of time to the individual at the end of life. The Palliative Care Yardstick, has been proposed as an alternative. In this paper, I argue that the QALY should not be abandoned as an outcome measure in end of life and palliative care populations and suggest possible methods for generating empirical data to support or refute this. I show why the arguments made for replacement of the QALY are not supported by current evidence and how in some cases the abandonment of the QALY framework would lead to an unjustifiable inequitable distribution of resources.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22591713     DOI: 10.1016/j.jhealeco.2012.01.006

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  16 in total

Review 1.  Economic impact of hospital inpatient palliative care consultation: review of current evidence and directions for future research.

Authors:  Peter May; Charles Normand; R Sean Morrison
Journal:  J Palliat Med       Date:  2014-07-01       Impact factor: 2.947

2.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

3.  An analysis of the construct validity and responsiveness of the ICECAP-SCM capability wellbeing measure in a palliative care hospice setting.

Authors:  Gareth Myring; Paul Mark Mitchell; W George Kernohan; Sonja McIlfatrick; Sarah Cudmore; Anne M Finucane; Lisa Graham-Wisener; Alistair Hewison; Louise Jones; Joanne Jordan; Laurie McKibben; Deborah H L Muldrew; Shazia Zafar; Joanna Coast
Journal:  BMC Palliat Care       Date:  2022-07-08       Impact factor: 3.113

Review 4.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

5.  A cost-utility analysis of a rehabilitation service for people living with and beyond cancer.

Authors:  Jeff Round; Baptiste Leurent; Louise Jones
Journal:  BMC Health Serv Res       Date:  2014-11-19       Impact factor: 2.655

Review 6.  The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.

Authors:  Anne B Wichmann; Eddy Mm Adang; Peep Fm Stalmeier; Sinta Kristanti; Lieve Van den Block; Myrra Jfj Vernooij-Dassen; Yvonne Engels
Journal:  Palliat Med       Date:  2017-02-13       Impact factor: 4.762

7.  Development of a Patient-Reported Palliative Care-Specific Health Classification System: The POS-E.

Authors:  Mendwas Dzingina; Irene J Higginson; Paul McCrone; Fliss E M Murtagh
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

8.  A framework for understanding quality of life in individuals without capacity.

Authors:  Jeff Round; Elizabeth L Sampson; Louise Jones
Journal:  Qual Life Res       Date:  2013-08-22       Impact factor: 4.147

9.  The agreement between proxy and self-completed EQ-5D for care home residents was better for index scores than individual domains.

Authors:  Angela Devine; Stephanie J C Taylor; Anne Spencer; Karla Diaz-Ordaz; Sandra Eldridge; Martin Underwood
Journal:  J Clin Epidemiol       Date:  2014-05-15       Impact factor: 6.437

10.  Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.

Authors:  Iftekhar Khan; Steve Morris; Nora Pashayan; Bashir Matata; Zahid Bashir; Joe Maguirre
Journal:  Health Qual Life Outcomes       Date:  2016-04-12       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.